Drug Trial Radar · NCT07244705
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Nov 2025
Primary completion
Apr 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Anbogen Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Fortrea
- First posted
- Nov 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of ABT-301 in combination with fixed doses of tislelizumab 200 mg IV infusion and bevacizumab 7.5 mg/kg IV infusion Q3W, in participants with pMMR/non-MSI-H colorectal cancer (CRC). It will also determine the maximum tolerated dose (MTD) and select the recommended Phase 2 dose (RP2D) of ABT-301. Participants will receive ABT-301 administered once daily (QD ±3 hours) or twice daily (Q12H ±3 hours, at least 9 hours apart) with water in 21-day treatment cycles. Tislelizumab 200 mg IV and bevacizumab 7.5 mg/kg IV Q3W will be given in both parts of the study.
Conditions
- Colorectal Cancer (Diagnosis)
- Colorectal Cancer Metastatic
- Colorectal Cancer (CRC)
- Immunotherapy
Interventions
ABT-301Drug
ABT-301 is an oral histone deacetylase inhibitor (HDACi) administered in capsule form once daily (QD ±3 hours) or every 12 hours (Q12H ±3 hours, with at least 9 hours between doses) with water in 21-day treatment cycles. In Part 1 (dose-escalation phase), participants receive escalating doses of ABT-301 (50 mg QD, 100 mg QD, 50 mg Q12H, 150 mg QD, or 75 mg Q12H). Tislelizumab 200 mg and bevacizumab 7.5 mg/kg will be administered through IV infusion on Day 1 of every 21-day treatment cycle. This phase aims to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of ABT-301 when combined with tislelizumab and bevacizumab. In Part 2 (dose-optimization phase), two ABT-301 doses/schedules will be selected for further evaluation of antitumor activity, safety, and tolerability in adults with pMMR/non-MSI-H colorectal cancer (CRC).
TislelizumabDrug
Tislelizumab is a humanized immunoglobulin G4-variant monoclonal antibody (mAb) blocking programmed cell death protein 1 (PD-1). Tislelizumab 200 mg will be administered through IV infusion on Day 1 of every 21-day treatment cycle in combination with ABT-301 and bevacizumab throughout both parts of the study.
Bevacizumab (Avastin)Drug
Bevacizumab (Avastin®) is a recombinant humanized monoclonal IgG1 antibody which binds to and neutralizes VEGF. Neutralization of VEGF by bevacizumab has been shown to inhibit the VEGF-induced proliferation of human endothelial cells in vitro and to decrease micro-vessel density and interstitial pressure in tumor xenografts in vivo. Bevacizumab 7.5 mg/kg will be administered through IV infusion on Day 1 of every 21-day treatment cycle in combination with ABT-301 and tislelizumab, throughout both parts of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part I - To evaluate the safety and tolerability of escalating doses of ABT-301 in combination with fixed doses of tislelizumab 200 mg IV infusion and bevacizumab 7.5 mg/kg IV infusion Q3W, in participants with pMMR/non-MSI-H CRC.Time frame: From screening to 90 days after last dose
- Part I - To determine the Maximum tolerated dose (MTD) and select the recommended Phase 2 dose (RP2D) of ABT-301.Time frame: From the first dose of ABT-301 to the completion of the first 21-day cycle of ABT-301 treatment in the last cohort.
- Part II - To evaluate the efficacy of two dosages/schemes of ABT-301 in combination with tislelizumab and bevacizumab.Time frame: From baseline until progression of disease or death, whichever occurs first. (up to 28 months)
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Liverpool Cancer Therapy Centre
Liverpool, New South Wales, Australia · Not yet recruiting
Macquarie University Hospital (MUH)
Macquarie Park, New South Wales, Australia · Not yet recruiting
Scientia Clinical Research
Randwick, New South Wales, Australia · Recruiting
Greenslopes Private Hospital - Cyril Gilbert Cancer Centre
Greenslopes, Queensland, Australia · Not yet recruiting
The Queen Elizabeth Hospital (TQEH)
Woodville South, South Australia, Australia · Not yet recruiting
Monash University - Faculty of Medicine, Nursing and Health Sciences
Clayton, Victoria, Australia · Not yet recruiting
Austin Health - Cancer Clinical Trials Centre (CCTC)
Heidelberg, Victoria, Australia · Not yet recruiting
Linear Clinical Research
Nedlands, Western Australia, Australia · Not yet recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan · Not yet recruiting
E-Da Cancer Hospital
Kaohsiung City, Taiwan · Not yet recruiting
Chang Gung Medical Foundation, Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan · Not yet recruiting
Taipei Medical University Shuang Ho Hospital, Ministry of Health and Welfare
New Taipei City, Taiwan · Not yet recruiting
National Cheng Kung University Hospital
Tainan, Taiwan · Not yet recruiting
National Taiwan University Hospital - Cancer Center
Taipei, Taiwan · Not yet recruiting
Chang Gung Medical Foundation, Linkou Chang Gung Memorial Hospital
Taoyuan, Taiwan · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.